PMID- 38168574 OWN - NLM STAT- MEDLINE DCOM- 20240505 LR - 20240508 IS - 1873-0183 (Electronic) IS - 1568-9972 (Linking) VI - 23 IP - 3 DP - 2024 Mar TI - Serum biomarkers and their relationship to axial spondyloarthritis associated with inflammatory bowel diseases. PG - 103512 LID - S1568-9972(23)00246-X [pii] LID - 10.1016/j.autrev.2023.103512 [doi] AB - Spondyloarthritis (SpA) constitute a group of chronic inflammatory immune-mediated rheumatic diseases characterized by genetic, clinical, and radiological features. Recent efforts have concentrated on identifying biomarkers linked to axial SpA associated with inflammatory bowel disease (IBD), offering predictive insights into disease onset, activity, and progression. Genetically, the significance of the HLA-B27 antigen is notably diminished in ankylosing spondylitis (AS) associated with IBD, but is heightened in concurrent sacroiliitis. Similarly, certain polymorphisms of endoplasmic reticulum aminopeptidase (ERAP-1) appear to be involved. Carriage of variant NOD2/CARD15 polymorphisms has been demonstrated to correlate with the risk of subclinical intestinal inflammation in AS. Biomarkers indicative of pro-inflammatory activity, including C-reactive protein (CRP) along with erythrocyte sedimentation rate (ESR), are among the consistent predictive biomarkers of disease progression. Nevertheless, these markers are not without limitations and exhibit relatively low sensitivity. Other promising markers encompass IL-6, serum calprotectin (s-CLP), serum amyloid (SAA), as well as biomarkers regulating bone formation such as metalloproteinase-3 (MMP-3) and Dickkopf-related protein 1 (DKK-1). Additional candidate indicators of structural changes in SpA patients include matrix metalloproteinase-3 (MMP-3), vascular endothelial growth factor (VEGF), tenascin C (TNC), and CD74 IgG. Fecal caprotein (f-CLP) levels over long-term follow-up of AS patients have demonstrated predictive value in anticipating the development of IBD. Serologic antibodies characteristic of IBD (ASCA, ANCA) have also been compared; however, results exhibit variability. In this review, we will focus on biomarkers associated with both axial SpA and idiopathic intestinal inflammation, notably enteropathic spondyloarthritis. CI - Copyright (c) 2024 The Authors. Published by Elsevier B.V. All rights reserved. FAU - Ondrejcakova, L AU - Ondrejcakova L AD - Institute of Rheumatology, Prague, Czech Republic; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic. FAU - Gregova, M AU - Gregova M AD - Institute of Rheumatology, Prague, Czech Republic; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic. FAU - Bubova, K AU - Bubova K AD - Institute of Rheumatology, Prague, Czech Republic; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic. Electronic address: bubova@revma.cz. FAU - Senolt, L AU - Senolt L AD - Institute of Rheumatology, Prague, Czech Republic; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic. Electronic address: senolt@revma.cz. FAU - Pavelka, K AU - Pavelka K AD - Institute of Rheumatology, Prague, Czech Republic; Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic. LA - eng PT - Journal Article PT - Review DEP - 20231231 PL - Netherlands TA - Autoimmun Rev JT - Autoimmunity reviews JID - 101128967 RN - 0 (Biomarkers) RN - 0 (HLA-B27 Antigen) RN - 0 (Leukocyte L1 Antigen Complex) RN - 9007-41-4 (C-Reactive Protein) SB - IM MH - Humans MH - *Biomarkers/blood MH - *Inflammatory Bowel Diseases/blood/immunology/diagnosis/complications MH - Axial Spondyloarthritis/blood/diagnosis MH - HLA-B27 Antigen/genetics/immunology MH - Spondylitis, Ankylosing/blood/diagnosis/immunology MH - Leukocyte L1 Antigen Complex/blood MH - C-Reactive Protein/analysis/metabolism OTO - NOTNLM OT - Ankylosing spondylitis OT - Axial spondyloarthritis OT - Biomarker OT - Enteropathic spondyloarthritis OT - Inflammatory bowel disease COIS- Declaration of Competing Iinterest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/01/04 01:18 MHDA- 2024/05/06 00:52 CRDT- 2024/01/03 10:48 PHST- 2023/12/15 00:00 [received] PHST- 2023/12/29 00:00 [accepted] PHST- 2024/05/06 00:52 [medline] PHST- 2024/01/04 01:18 [pubmed] PHST- 2024/01/03 10:48 [entrez] AID - S1568-9972(23)00246-X [pii] AID - 10.1016/j.autrev.2023.103512 [doi] PST - ppublish SO - Autoimmun Rev. 2024 Mar;23(3):103512. doi: 10.1016/j.autrev.2023.103512. Epub 2023 Dec 31.